Azerbaijan granted permission to study Sputnik V and AstraZeneca vaccine combination

09 February 2021

 

Azerbaijan has issued permission to conduct the world's first study of a combination of coronavirus vaccines - Sputnik V and AstraZeneca, according to a press release from the Russian Direct Investment Fund (RDIF).


It is noted that clinical trials of the vaccine combination will begin in February 2021.


"The studies are expected to evaluate the immunogenicity and safety of the combined use of the Sputnik V vaccine and the vaccine developed by AstraZeneca together with Oxford University. The research program will last six months on the territory of several countries, 100 volunteers are planned to be involved in each study of the program", - is noted in the message.

 

 

The RDIF adds that the studies will evaluate the immunogenicity and safety of the combined vaccine use.


Previously, the RDIF, the Gamaleya Research Center, AstraZeneca, and R-Pharm signed a memorandum of cooperation in the development of a coronavirus vaccine, which was announced in December 2020 in the presence of Russian President Vladimir Putin.


The world's first vaccine collaboration is being conducted as part of a clinical trial protocol registered on December 24, 2020.

 

 

GSV "Russia - Islamic World"

Photo: sputnikvaccine.com

Based on materials from TASS